Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05337124 · ClinicalTrials.gov registry record
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
A clinical trial, sponsored by Aurinia Pharmaceuticals.
- Completed
- Registry status
- 229
- Enrollment target
NCT05337124 is a clinical trial that has completed, run by Aurinia Pharmaceuticals. The registered enrollment target is 229 participants.
The verdict
NCT05337124 has completed, sponsored by Aurinia Pharmaceuticals.
- COMPLETED
- Registry status
- 229 participants
- Enrollment target
Study Summary
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
Interventions
- DRUG LUPKYNIS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 229 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05337124
The ClinicalTrials.gov registry entry for NCT05337124 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 229 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aurinia Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LUPKYNIS is the first listed.
NCT05337124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05337124 about?
NCT05337124 is a clinical study titled "A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US". This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
What is the current status of trial NCT05337124?
This trial is currently completed. The enrollment target is 229 participants. The study started on 2022-04-05. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05337124?
The interventions under investigation include: LUPKYNIS (DRUG).
Who is sponsoring clinical trial NCT05337124?
This trial is sponsored by Aurinia Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.